Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on September 14, 2026. The report addresses a specific corporate event under Item 8.01 (Other Events) regarding a clinical development milestone for the company's asset PH-762.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a non-financial operational update.
Material Changes and Operational Updates
- PH-762 Milestone: The company announced a key development milestone for PH-762.
- FDA Submission: Materials were submitted to the U.S. Food and Drug Administration (FDA) to support the next phase of clinical development for cutaneous cell carcinoma.
- Future Studies: A planned Phase 2b neoadjuvant study was announced.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the announcement but does not contain explicit forward-looking financial guidance, management commentary on financial performance, or a discussion of risks and contingencies within the body of this specific 8-K text.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for detailed clinical data.
- Verify the specific indications and endpoints for the planned Phase 2b neoadjuvant study.
- Confirm the status of the FDA submission and any anticipated timelines for regulatory feedback.
- Check subsequent filings for any financial impact or capital requirements related to the new clinical phase.